Skip to main content
. 2022 Aug 15;12(8):3693–3712.

Figure 3.

Figure 3

Abnormal expression of Ku80, FOXF2 correlates with clinical characteristics of colon cancer patients. (A) Immunohistochemical scores of Ku80 and (B) FOXF2 expression in colon cancer and normal control group; (C) Ku80 expression in colon tissues: (a) Negative; (b) Weakly positive; (c) Positive; (d) Strongly positive. Expression of Ku80 in colon cancer tissues: (e) Negative; (f) Weakly positive; (g) Positive; (h) Strong positive. (D) FOXF2 expression in colon tissues: (a) Negative; (b) Weakly positive; (c) Positive; (d) Strongly positive. Expression of FOXF2 in colon cancer tissues: (e) Negative; (f) Weakly positive; (g) Positive; (h) Strong positive. SP ×400; (E) The transcriptional expression of Ku80 (XRCC5) in pan-cancer; (F) The transcriptional expression of KDM1A (LSD1) in pan-cancer; (G) The transcriptional expression of FOXF2 in pan-cancer. (H) XRCC5 is expressed at the transcription level in the colon cancer dataset; (I) KDM1A is expressed at the transcription level in the colon cancer dataset; (J) FOXF2 is expressed at the transcription level in the colon cancer dataset; (K) XRCC5 is positively correlated with the expression of KDM1A (LSD1); (L) KDM1A (LSD1) is negatively correlated with FOXF2 expression; (M) XRCC5 is negatively correlated with FOXF2 expression.